

DIMERIX ANNOUNCES UPDATE ON SUCCESSFUL CAPITAL RAISING INITIATIVE

Key Highlights

- **Dimerix raises ~\$8.7 million, through a combination of entitlement offer and convertible notes:**
 - **\$5.2 million raised from rights issue with strong take up from eligible shareholders**
 - **Dimerix has received \$1.6 million of the initial tranche of \$3.5 million from the Convertible Securities Agreement with a US based investment fund, with a further \$1.9 million expected subject to shareholder approval**
- **Funds raised to continue the Company's Phase 3 FSGS clinical program past 1st interim data, including clinical, inclusion of paediatric patients, manufacturing and partnering activities**

MELBOURNE, Australia, 5 June 2023: Dimerix Limited (ASX:DXB) (**Dimerix** or the **Company**) is pleased to provide the following update in respect of the capital raising initiatives of the Company as announced to ASX on 4 May 2023.

Capitalised terms in this announcement that are not defined in this announcement are as defined in the prospectus lodged with ASIC and released to ASX on 4 May 2023 (**Prospectus**).

Rights Issue

The Company is pleased to advise that it has received subscriptions for \$5,205,960 under the Rights Issue. 65,074,494 New Shares together with 65,074,746 free-attaching New Options are to be issued shortly and an Appendix 2A and 3G for the issue will be released to ASX at or about the same time as the issue.

The Board expresses their thanks for the support provided by participants in the Rights Issue.

Further details of the breakdown of the amount raised under the Rights Issue is set out below.

The Rights Issue closed at 5pm (Melbourne time) on 29 May 2023. The Company received subscriptions for \$3,142,260 (39,278,252 New Shares together with 39,278,496 free-attaching New Options) from Eligible Shareholders, inclusive of Shortfall subscriptions. The Company thanks shareholders for their participation in the rights issue.

The maximum number of New Shares and New Options offered under the Rights Issue was 106,957,889 and accordingly the Shortfall was 67,679,637 New Shares and New Options.

Of the Shortfall, the Underwriter (including via sub-underwriters as described in the Prospectus) subscribed or procured subscriptions for an aggregate of \$2,063,699 (25,796,242 New Shares together with 25,796,250 free-attaching New Options) in accordance with the terms of the Underwriting Agreement as described in the Prospectus. The Company thanks the Underwriter for its role in connection with the Rights Issue.

The Company will issue 5,877,692 Long Term New Options to sub-underwriters of the Rights Issue (as and when identified by the Underwriter) who are not related parties of the Company. These Long Term New Options are expected to be issued in the coming days. The issue of Long Term New Options to related party sub-underwriters is subject to shareholder approval which will be sought at the general meeting convened for 20 June 2023.

As part of the Rights Issue capital raising initiative and as set out in the Prospectus, the Company reserved the right to offer and issue the remaining 41,883,395 New Shares and New Options from the Shortfall at its discretion on or before the date that is three months after the Closing Date (being on or before 29 August 2023).

Convertible Securities Facility

On 25 May 2023, the Company issued 1,760,000 Notes and 1,875,000 New Shares to Mercer Street Global Opportunity Fund, LLC, a US-based investment fund managed by Mercer Street Capital Partners, LLC (together, **Mercer**) for a subscription sum of \$1.6 million, in accordance with the terms of the CSA. An Appendix 3G for the issue of Notes and an Appendix 2A for the issue of New Shares were each released to ASX on 25 May 2023.

The issue of a further 2,090,000 Notes (\$1.9 million subscription sum) and 11,363,636 Long Term New Options to Mercer under the CSA are subject to shareholder approval which is being sought at the general meeting convened for 20 June 2023. Further details are set out in the Notice of General Meeting dated 22 May 2023 and released to ASX on that date.

The Board thanks Mercer for its support of the Company.

Released with the authority of the Board.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on [LinkedIn](#) and [Twitter](#)

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, in a Phase 3 clinical study for Focal Segmental Glomerulosclerosis (FSGS), and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.